Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Insects|August 25, 2022
Pharmacological Properties and Function of the PxOctβ3 Octopamine Receptor in Plutella xylostella (L.)Hang Zhu, Zheming Liu, Haihao Ma, et al.
Anti-Cancer Drugs|August 4, 2018
Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell linesYanqiong Chen, Guoliang Ma, Cuiyun Su, et al.
Chemosphere|September 1, 2021
Can the multi-walled carbon nanotubes be used to alleviate the phytotoxicity of herbicides in soils?Ting Yao, Lejun Liu, Shuo Tan, et al.
Free Radical Biology & Medicine|January 13, 2018
Gut flora-dependent metabolite Trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stressYilang Ke, Dang Li, Mingming Zhao, et al.
Aging Cell|May 12, 2018
Trimethylamine-N-oxide promotes brain aging and cognitive impairment in miceDang Li, Yilang Ke, Rui Zhan, et al.
Insects|April 21, 2022
C/EBPα Regulates PxTreh1 and PxTreh2 Trehalase-Related Bt Resistance in Plutella xylostella (L.)Jia Liu, Zheming Liu, Haihao Ma, et al.
Frontiers in Plant Science|October 29, 2021
Anthocyanin Genes Involved in the Flower Coloration Mechanisms of Cymbidium kanranZhuang Zhou, Zhen Ying, Zhigang Wu, et al.
Viruses|June 27, 2025
Strain-Divergent m6A Landscapes Modulate Nipah Virus Replication and METTL3 Inhibition Attenuates VirulenceTing Luo, Zhen Chen, Fang Zhang, et al.
Frontiers in Immunology|December 26, 2022
PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort studyShubin Chen, Haowen Wei, Wenhua Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 14, 2026
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50Mark A Socinski, Martin Reck, Luis Paz-Ares, et al.
Pageof 4